Basit öğe kaydını göster

dc.contributor.authorSul, Sabahattin
dc.contributor.authorKaralezli, Aylin
dc.contributor.authorKarabulut, Mujdat
dc.date.accessioned2020-11-20T14:42:39Z
dc.date.available2020-11-20T14:42:39Z
dc.date.issued2019
dc.identifier.issn1300-0659
dc.identifier.issn2147-2661
dc.identifier.urihttps://doi.org/10.4274/tjo.galenos.2018.76429
dc.identifier.urihttps://app.trdizin.gov.tr//makale/TXpjME9USTVPUT09
dc.identifier.urihttps://hdl.handle.net/20.500.12809/1096
dc.descriptionKaralezli, Aylin/0000-0003-1316-4656; , mujdat/0000-0002-7844-5638; sul, sabahattin/0000-0003-4812-7636en_US
dc.descriptionWOS: 000459824600005en_US
dc.descriptionPubMed ID: 30829020en_US
dc.description.abstractObjectives: To compare the first-year results of patients with active neovascular age-related macular degeneration (nAMD) under intravitreal ranibizumab (IVR) treatment who did and did not undergo cataract surgery. Materials and Methods: The records of 72 patients with active nAMD were reviewed retrospectively. Group 1 consisted of 23 patients who underwent uncomplicated cataract surgery and continued with IVR treatment and group 2 consisted of 49 patients without cataract who received only IVR treatment. The groups were compared according to pretreatment and first year best spectacle-corrected visual acuity (BCVA), central foveal thickness (CFT), number of injections, and nAMD activity (presence of subretinal or intraretinal fluid). Logarithm of minimum angle of resolution (LogMAR) was used for the determination of visual acuity. Activity findings were evaluated with optical coherence tomography. Results: Pretreatment BCVA was 0.94 +/- 0.21 in group 1 and 0.77 +/- 0.36 in group 2 (p=0.041). At the end of the first year, BCVA was 0.48 +/- 0.35 in group 1 and 0.49 +/- 0.33 in group 2 (p=0.902). BCVA change was 0.46 +/- 0.29 in group 1 and 0.28 +/- 0.31 in group 2 (p=0.026). Pretreatment CFT was 305 +/- 146 mu m in group 1 and 340 +/- 120 mu m in group 2 (p=0.292). At the end of the first year, CFT was 246 +/- 110 mu m and 245 +/- 82 mu m in group 2 (p=0.977). CFT change was 59 +/- 45 mu m in group 1 and 92 +/- 97 mu m in group 2 (p=0.135). Mean number of injections over 1 year was 6.2 +/- 1.9 in group 1 and 5.7 +/- 1.8 in group 2 (p=0.271). At the end of the first year, subretinal fluid was observed in 3 patients in group 1 (13%) and 5 patients in group 2 (10.2%) (p=0.721) and intraretinal fluid was present in 3 patients in group 1 (13%) and 4 patients in group 2 (8.2%) (p=0.515). Conclusion: Cataract surgery combined with IVR treatment yielded significant visual gain in patients with active nAMD. Anatomic results suggest that cataract surgery does not worsen nAMD.en_US
dc.item-language.isoengen_US
dc.publisherTurkish Ophthalmological Socen_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNeovascular Age-Related Macular Degenerationen_US
dc.subjectRanibizumaben_US
dc.subjectCataract Surgeryen_US
dc.titleFirst-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degenerationen_US
dc.item-typearticleen_US
dc.contributor.departmenten_US
dc.contributor.departmentTemp[Sul, Sabahattin; Karalezli, Aylin; Karabulut, Mujdat] Mugla Sitki Kocman Univ, Fac Med, Dept Ophthalmol, Mugla, Turkeyen_US
dc.identifier.doi10.4274/tjo.galenos.2018.76429
dc.identifier.volume49en_US
dc.identifier.issue1en_US
dc.identifier.startpage15en_US
dc.identifier.endpage19en_US
dc.relation.journalTurk Oftalmoloji Dergisi-Turkish Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster